How it works

Cagrilintide is a long-acting analog of amylin, a hormone released alongside insulin that signals fullness. In research it has been reported to slow gastric emptying, promote satiety (a feeling of fullness), and support body-weight reduction in study models, particularly when paired with GLP-1 compounds.

For laboratory and research use only — not for human or veterinary consumption.

Cagrilintide (10 mg) — Long-Acting Synthetic Amylin Analog

Cagrilintide is a synthetic, long-acting analog of human amylin (IAPP), supplied as a lyophilized powder for laboratory research. For laboratory and research use only — not for human or veterinary consumption, not a drug, food, cosmetic, or dietary supplement, and not for any diagnostic, therapeutic, clinical, or in vivo use.

Compound identity: synthetic peptide analog of the amylin (IAPP) family. In the research literature, amylin analogs of this class are characterized as agonists at the amylin receptor family (calcitonin receptor with RAMP1/2/3, forming AMY1–AMY3 subtypes); acylation is reported to extend half-life relative to native amylin.

Researched applications (literature context only; no human effect claimed): receptor-binding and signal-transduction assays; peptide structure–activity and stability studies; in vitro metabolic-signaling research; analytical-method reference work.

Specifications — Form: lyophilized powder, per vial. Vial size: 10 mg. Purity: HPLC >=99%. Identity: mass spectrometry. CAS: 2018899-19-9. COA per lot. Storage: -20°C, protect from light/moisture; shipped cold-chain.

For laboratory and research use only (RUO). Not for human or veterinary use.